Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1645
This examiner grants 53% of resolved cases
Patricia Ann Duffy is an examiner in Tech Center 1600, working within Art Unit 1644. She has a record of 573 resolved cases. This experience level in the biotechnology and organic chemistry fields indicates a deep familiarity with the complex legal and technical requirements of Tech Center 1600. Her case history provides a reliable basis for analyzing her examination patterns.
Her allowance rate stands at 52.9 percent. A particularly striking data point is the interview lift of 33.9 percent. This is a very high lift, suggesting that interviews are exceptionally effective at overcoming hurdles in her examination process. For practitioners, this 33.9 percent increase in allowance probability after an interview represents a clear tactical recommendation. Direct communication appears to be a primary driver for moving applications toward a grant in her art unit.
The median days to allowance for her cases is 1327. This duration is relatively long, reflecting the typical complexities and rigorous review processes found in biotechnology prosecution. When combined with the 52.9 percent allowance rate, the 1327-day median suggests that while the path to allowance is challenging and time-consuming, it is significantly aided by the use of interviews. Applicants should budget for a longer prosecution timeline while prioritizing early examiner contact to leverage the 33.9 percent lift.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18178819 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17350898 | IL-10-CONTAINING VACCINES AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18684437 | PAENIBACILLUS STRAINS PRODUCING LOW AMOUNTS OF EXOPOLYSACCARIDES | Non-Final OA | BASF SE |
| 19309183 | CHIMERIC NEUROTOXINS | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18506636 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN CHLAMYDIAL INFECTIONS AND DISEASES USING ATTENUATED ANIMAL CHLAMYDIA | Non-Final OA | Board of Regents, The University of Texas System |
| 18318062 | ENDOLYSOSOMAL TARGETING CONJUGATES FOR IMPROVED DELIVERY OF CARGO MOLECULES TO THE ENDOLYSOSOMAL COMPARTMENT OF TARGET CELLS | Non-Final OA | Board of Regents of the University of Texas System |
| 18681192 | LEPTOSPIRAL VIRULENCE MODULATING PROTEINS AND USES THEREOF | Non-Final OA | Yale University |
| 18293007 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES | Final Rejection | Intervet Inc. |
| 18661538 | COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING MALARIA | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18580713 | PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18234902 | GENETICALLY MODIFIED BACTERIA FOR GENERATING VACCINES | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18712227 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIA | Non-Final OA | NOVAVAX, INC. |
| 18718636 | VACCINE | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18686089 | Shigella Vaccine | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18256749 | Hyper-Blebbing Bacteria | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18698698 | Novel Strain Having Antagonism Against Proteus Mirabilis and Excellent Effect on Neurodegenerative Disease, and use Thereof | Non-Final OA | METACEN THERAPEUTICS CO., LTD |
| 18688067 | COMPOSITIONS COMPRISING BACILLUS AMYLOLIQUEFACIENS FOR PREVENTING AND TREATING ULCERATIVE COLITIS | Non-Final OA | Artugen Therapeutics Ltd. |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | Non-Final OA | SEAGEN INC. |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy